A model structure for describing uncertainties in benefit-risk assessment of oncology drug applications
The proposed CATS model structure may facilitate communicating uncertainties in the benefit-risk assessment of drug applications. Further refinements, depending on the purpose and validation, aiming at broader applicability, are needed.
Authors
- Martin Posch (ORCID: https://orcid.org/0000-0001-8499-8573)
- Francesco Pignatti (ORCID: https://orcid.org/0000-0001-9296-2474)
- Andreas Kouroumalis
- Anne C. Taams (ORCID: https://orcid.org/0000-0002-3002-3911)
- Lourens T. Bloem (ORCID: https://orcid.org/0000-0002-0014-8625)
- Nikolaos Zafiropoulos
- Rosanne Janssens (ORCID: https://orcid.org/0000-0003-1982-4176)
- Dominik Karres (ORCID: https://orcid.org/0009-0008-6773-622X)
- Lorenzo Guizzaro (ORCID: https://orcid.org/0000-0002-0390-270X)
- Olli Tenhunen
- Pierre Démolis
- Franz Koenig
Institutions
- European Medicines Agency (NL)
- Utrecht University (NL)
- Oulu University Hospital (FI)
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (FR)
- Medicines Evaluation Board (NL)
- Finnish Medicines Agency Fimea (FI)
- Medical University of Vienna (AT)
- KU Leuven (BE)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-10-15
- DOI
- https://doi.org/10.3389/fmed.2025.1589578
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- FP7 Health